Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions
The development of vaccines against RNA viruses has undergone a rapid evolution in recent years, particularly driven by the COVID-19 pandemic. This review examines the key roles that RNA viruses, with their high mutation rates and zoonotic potential, play in fostering vaccine innovation. We also dis...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/12/12/1345 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850238937523552256 |
|---|---|
| author | Kuei-Ching Hsiung Huan-Jung Chiang Sebastian Reinig Shin-Ru Shih |
| author_facet | Kuei-Ching Hsiung Huan-Jung Chiang Sebastian Reinig Shin-Ru Shih |
| author_sort | Kuei-Ching Hsiung |
| collection | DOAJ |
| description | The development of vaccines against RNA viruses has undergone a rapid evolution in recent years, particularly driven by the COVID-19 pandemic. This review examines the key roles that RNA viruses, with their high mutation rates and zoonotic potential, play in fostering vaccine innovation. We also discuss both traditional and modern vaccine platforms and the impact of new technologies, such as artificial intelligence, on optimizing immunization strategies. This review evaluates various vaccine platforms, ranging from traditional approaches (inactivated and live-attenuated vaccines) to modern technologies (subunit vaccines, viral and bacterial vectors, nucleic acid vaccines such as mRNA and DNA, and phage-like particle vaccines). To illustrate these platforms’ practical applications, we present case studies of vaccines developed for RNA viruses such as SARS-CoV-2, influenza, Zika, and dengue. Additionally, we assess the role of artificial intelligence in predicting viral mutations and enhancing vaccine design. The case studies underscore the successful application of RNA-based vaccines, particularly in the fight against COVID-19, which has saved millions of lives. Current clinical trials for influenza, Zika, and dengue vaccines continue to show promise, highlighting the growing efficacy and adaptability of these platforms. Furthermore, artificial intelligence is driving improvements in vaccine candidate optimization and providing predictive models for viral evolution, enhancing our ability to respond to future outbreaks. Advances in vaccine technology, such as the success of mRNA vaccines against SARS-CoV-2, highlight the potential of nucleic acid platforms in combating RNA viruses. Ongoing trials for influenza, Zika, and dengue demonstrate platform adaptability, while artificial intelligence enhances vaccine design by predicting viral mutations. Integrating these innovations with the One Health approach, which unites human, animal, and environmental health, is essential for strengthening global preparedness against future RNA virus threats. |
| format | Article |
| id | doaj-art-98cdeebd59514df9965e4f5c813c575d |
| institution | OA Journals |
| issn | 2076-393X |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-98cdeebd59514df9965e4f5c813c575d2025-08-20T02:01:19ZengMDPI AGVaccines2076-393X2024-11-011212134510.3390/vaccines12121345Vaccine Strategies Against RNA Viruses: Current Advances and Future DirectionsKuei-Ching Hsiung0Huan-Jung Chiang1Sebastian Reinig2Shin-Ru Shih3Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan 33302, TaiwanResearch Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan 33302, TaiwanResearch Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan 33302, TaiwanResearch Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan 33302, TaiwanThe development of vaccines against RNA viruses has undergone a rapid evolution in recent years, particularly driven by the COVID-19 pandemic. This review examines the key roles that RNA viruses, with their high mutation rates and zoonotic potential, play in fostering vaccine innovation. We also discuss both traditional and modern vaccine platforms and the impact of new technologies, such as artificial intelligence, on optimizing immunization strategies. This review evaluates various vaccine platforms, ranging from traditional approaches (inactivated and live-attenuated vaccines) to modern technologies (subunit vaccines, viral and bacterial vectors, nucleic acid vaccines such as mRNA and DNA, and phage-like particle vaccines). To illustrate these platforms’ practical applications, we present case studies of vaccines developed for RNA viruses such as SARS-CoV-2, influenza, Zika, and dengue. Additionally, we assess the role of artificial intelligence in predicting viral mutations and enhancing vaccine design. The case studies underscore the successful application of RNA-based vaccines, particularly in the fight against COVID-19, which has saved millions of lives. Current clinical trials for influenza, Zika, and dengue vaccines continue to show promise, highlighting the growing efficacy and adaptability of these platforms. Furthermore, artificial intelligence is driving improvements in vaccine candidate optimization and providing predictive models for viral evolution, enhancing our ability to respond to future outbreaks. Advances in vaccine technology, such as the success of mRNA vaccines against SARS-CoV-2, highlight the potential of nucleic acid platforms in combating RNA viruses. Ongoing trials for influenza, Zika, and dengue demonstrate platform adaptability, while artificial intelligence enhances vaccine design by predicting viral mutations. Integrating these innovations with the One Health approach, which unites human, animal, and environmental health, is essential for strengthening global preparedness against future RNA virus threats.https://www.mdpi.com/2076-393X/12/12/1345RNA virusvaccine platformRNA virus vaccinesSARS-CoV-2influenza virusenterovirus |
| spellingShingle | Kuei-Ching Hsiung Huan-Jung Chiang Sebastian Reinig Shin-Ru Shih Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions Vaccines RNA virus vaccine platform RNA virus vaccines SARS-CoV-2 influenza virus enterovirus |
| title | Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions |
| title_full | Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions |
| title_fullStr | Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions |
| title_full_unstemmed | Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions |
| title_short | Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions |
| title_sort | vaccine strategies against rna viruses current advances and future directions |
| topic | RNA virus vaccine platform RNA virus vaccines SARS-CoV-2 influenza virus enterovirus |
| url | https://www.mdpi.com/2076-393X/12/12/1345 |
| work_keys_str_mv | AT kueichinghsiung vaccinestrategiesagainstrnavirusescurrentadvancesandfuturedirections AT huanjungchiang vaccinestrategiesagainstrnavirusescurrentadvancesandfuturedirections AT sebastianreinig vaccinestrategiesagainstrnavirusescurrentadvancesandfuturedirections AT shinrushih vaccinestrategiesagainstrnavirusescurrentadvancesandfuturedirections |